Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAIM ImmunoTech Inc.

AIM ImmunoTech Inc.

PortfolioPortfolio WatchlistWatchlist
Company price
0.169 GBX 0.00(0%)
Last update at 2026-10-27T17:28:00Z
VOLUME
2188
Market Cap
0.00M

Momentum Score

…

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.16
Low
0.17
High
52 Week Price Range
0.52
Low
10.49
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.17
Dividend Yield
-
Revenue TTM
0.09M
Revenue Per Share
0.05
Gross Profit TTM
-0.04M
Debt / Equity
0.03
ROE
-3138.91%
Net Debt
-
ROCE
-26.87%
Diluted EPS TTM
-0.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax - -14.40M -9.40M -9.81M -8.26M
Net income - -14.40M -9.40M -9.81M -8.26M
Selling general administrative - 8.65M 7.04M 6.20M 6.57M
Gross profit - -0.64M -0.75M -0.52M -0.75M
Ebit -17.06M -14.86M -12.44M -11.46M -11.41M
Operating income - -15.01M -11.57M -11.02M -11.42M
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income - 0.45M 0.25M 1.04M 0.05M
Total revenue - 0.16M 0.14M 0.37M 0.44M
Cost of revenue - 0.81M 0.89M 0.88M 1.18M
Net income applicable to common shares -19.13M -14.40M -9.40M -9.83M -8.26M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets - 64.58M 20.75M 13.85M 14.21M
Intangible assets - 1.50M 1.15M 0.91M 0.86M
Other current assets - - - - 0.76M
Total liab - 3.29M 7.31M 8.67M 5.50M
Total stockholder equity - 61.29M 13.44M 5.17M 8.70M
Common stock 0.05M 0.04M 0.01M 0.00M 0.03M
Retained earnings -361.10M -341.97M -327.57M -318.58M -308.76M
Other liab 0.04M 0.18M 0.06M 1.06M 0.96M
Other assets 1.32M 0.75M 1.89M 1.35M 1.26M
Cash - 38.50M 1.47M 0.30M 1.41M
Total current liabilities 0.67M 1.10M 1.13M 5.29M 2.71M
Short term debt - - - 3.41M -
Short long term debt total - 1.88M 6.01M 2.32M 1.83M
Other stockholder equity - -0.05M - - 0.01M
Property plant equipment 4.20M 6.65M 7.27M 7.78M 8.59M
Total current assets 50.21M 40.31M 10.45M 3.80M 3.50M
Net tangible assets 54.19M 59.06M 11.51M 4.26M 7.84M
Short term investments - 0.50M 7.31M 1.53M 0.69M
Net receivables 1.64M 1.12M 0.82M 1.09M 0.02M
Long term debt - - 3.91M - 1.83M
Accounts payable 0.20M 0.38M 0.47M 0.68M 0.74M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - - -0.24M -8.57M
Change to liabilities - - - -0.18M -0.09M
Total cashflows from investing activities - - - -0.63M -9.16M
Net borrowings - - - -4.85M -4.68M
Total cash from financing activities - - - 8.19M 56.56M
Change to operating activities - - - 1.05M 0.65M
Net income -17.32M -28.96M -19.45M -19.13M -14.40M
Change in cash - - - -6.41M 37.03M
Total cash from operating activities - - - -13.96M -10.37M
Depreciation - - - 0.78M 0.73M
Other cashflows from investing activities - - - - -8.57M
Change to account receivables - - - 0.03M 0.04M
Sale purchase of stock - - - - 61.25M
Change to netincome - - - 3.44M 2.58M
Capital expenditures 0.00M 0.00M 0.00M 0.04M 0.02M
Change in working capital - - - - 0.60M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0A4Y
AIM ImmunoTech Inc.		 -
-%		 0.17 - - - -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

2117 SW Highway 484, Ocala, FL, United States, 34473

352 448 7797

https://aimimmuno.com

19

Name Title Year Born
Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President 1953
Mr. Robert Dickey IV Chief Financial Officer 1956
Mr. Peter W. Rodino III, Esq., J.D. COO, Executive Director of Governmental Relations, General Counsel & Secretary 1951
Ann Marie E. Coverly Director of Administration & Human Resources and Deputy Investor Relations Coordinator NA
Dr. Christopher Nicodemus FACP, M.D. Member of Scientific Advisory Board & Consulting Science Officer NA
Mr. Robert Dickey IV, B.A., M.B.A. Chief Financial Officer 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…